NCT05644223

Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke

Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke: a Multicenter, Prospective, Patient-centered, Real-world Cohort Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 4,750 (estimated)
• Sponsor: Xuanwu Hospital, Beijing · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, prospective, cohort study to observe the clinical efficacy and safety of edaravone dextrol in patients with acute ischemic stroke in a real-world setting.

Detailed description

The study lasts a total of 90 days and includes three phases: screening, treatment, and follow-up. Treatment period: patients are divided into exposure group and non-exposed group based on the use of edaravone dextrol after ischemic stroke. The exposure group: edaravone dextrol is used according to reference to clinical practice, without specific restrictions. The non-exposed group: edaravone dextrol is not used, and concomitant therapy is at the clinician's discretion. Follow-up period: All patients continue to be followed up to 90 days after stroke onset.

Conditions

• Acute Ischemic Stroke

Interventions

Type	Name	Description
DRUG	edaravone dexborneol	intravenous edaravone dexborneol 37.5mg twice daily

Timeline

• Start date: 2023-01-01
• Primary completion: 2024-06-30
• Completion: 2024-06-30
• First posted: 2022-12-09
• Last updated: 2023-08-31

Locations

1 site across 1 country: China